基线肿瘤大小作为非小细胞肺癌免疫检查点抑制剂治疗的预测和预后因素
Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer.
作者信息
Katsurada Masahiro, Nagano Tatsuya, Tachihara Motoko, Kiriu Tatsunori, Furukawa Koichi, Koyama Kiyoko, Otoshi Takehiro, Sekiya Reina, Hazama Daisuke, Tamura Daisuke, Nakata Kyosuke, Katsurada Naoko, Yamamoto Masatsugu, Kobayashi Kazuyuki, Nishimura Yoshihiro
机构信息
Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
出版信息
Anticancer Res. 2019 Feb;39(2):815-825. doi: 10.21873/anticanres.13180.
BACKGROUND/AIM: Immune checkpoint inhibitors (ICI) are a novel medication for non-small cell lung cancer (NSCLC). Recent reports indicated that baseline tumor size (BTS) relates to the efficacy of ICI therapy for melanoma, but no study exists for NSCLC. This study aimed to evaluate the utility of BTS for ICI therapy.
PATIENTS AND METHODS
Data from 58 patients diagnosed with NSCLC who underwent ICI monotherapy, were retrospectively analyzed. Patients were divided into two groups according to BTS (below 101 mm, above 101 mm). The primary endpoint was progression-free survival (PFS) and the secondary endpoint was overall survival (OS).
RESULTS
PFS of patients with a large BTS was significantly shorter than that of those with a small BTS (median; 2.07 [95% confidence interval [CI]=0.99-6.77] months versus 6.39 [95%CI=4.17-11.50] months) (p=0.044). OS of patients with large BTS was also significantly shorter (p<0.01).
CONCLUSION
BTS is a predictive and prognostic negative factor of ICI therapy for NSCLC.
背景/目的：免疫检查点抑制剂（ICI）是一种用于非小细胞肺癌（NSCLC）的新型药物。最近的报告表明，基线肿瘤大小（BTS）与ICI治疗黑色素瘤的疗效相关，但尚无针对NSCLC的研究。本研究旨在评估BTS对ICI治疗的效用。
患者与方法
对58例接受ICI单药治疗的NSCLC患者的数据进行回顾性分析。根据BTS（101mm以下、101mm以上）将患者分为两组。主要终点为无进展生存期（PFS），次要终点为总生存期（OS）。
结果
BTS大的患者的PFS明显短于BTS小的患者（中位数；2.07 [95%置信区间[CI]=0.99 - 6.77]个月对6.39 [95%CI = 4.17 - 11.50]个月）（p = 0.044）。BTS大的患者的OS也明显较短（p < 0.01）。
结论
BTS是NSCLC患者ICI治疗的预测和预后负性因素。
Zotero 插件